CureVac has filed 266 patents.
When was CureVac founded?
CureVac was founded in 2000.
Where is CureVac's headquarters?
CureVac's headquarters is located at Friedrich-Miescher-Str. 15, Tubingen.
What is CureVac's latest funding round?
CureVac's latest funding round is IPO.
How much did CureVac raise?
CureVac raised a total of $1.281B.
Who are the investors of CureVac?
Investors of CureVac include GSK, Qatar Investment Authority, European Investment Bank, KfW, European Commission and 14 more.
Who are CureVac's competitors?
Competitors of CureVac include Ethris.
You May Also Like
ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics. ReCode’s lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. ReCode is leveraging its SORT LNP platform and nucleic acid technologies to expand its pipeline with therapeutics that use mRNA-mediated replacement and gene correction in target organs with precision targeting of disease-relevant cells. Recode Therapeutics was founded in 2015 and is based in Menlo Park, California.
Ethris is paving a new path from genes to therapeutic proteins using its messenger RNA technology platform, which enables the discovery, design and development of transcript therapies that restore missing functions in patients' cells and tissues. Ethris is advancing transcript therapies to transform the treatment of disease.
BioNTech is developing personalized immunotherapies to help the treatment of people with cancer and other debilitating diseases.
Moderna Therapeutics (NASDAQ:MRNA) is a Cambridge, Massachusetts-based biotechnology company that is focused on drug discovery and drug development based on messenger RNA. The company creates synthetic mRNA that can be injected into patients to help them create their own therapies.
Arcturus Therapeutics (NASDAQ: ARCT) focuseS on the discovery and development of therapeutic modalities to pursue RNA interference (RNAi) solutions for rare diseases for which there is no adequate treatment.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.